News and Trends 6 Apr 2017 Biotech Targeting Tau-Tangles in Neurodegeneration Initiates Clinical Trials Swiss Asceneuron has received regulatory approval to start its first Phase I trial of ASN120290, which is indicated for the treatment of dementia. Asceneuron was founded in 2012 as a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio. Its key asset ASN120290 is an inhibitor of the O-GlcNAcase enzyme and is indicated for the treatment of diseases associated […] April 6, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 10 Mar 2017 Galapagos finds a Partner to Boost its Pipeline with Drug Combinations Galapagos and Pharnext will work together to develop low-dose drug combinations that improve drug efficacy and target new indications. Galapagos, the biggest biotech in Belgium, has closed an R&D agreement with the French Pharnext to develop drug combinations of the billion-euro biotech’s drug candidates with already approved drugs. While Pharnext’s focus has been neurodegenerative diseases, the […] March 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2017 French Biotech bids for Crowdfunding in Neurodegenerative Disease AlzProtect is aiming to raise €1M via equity crowdfunding to fund a Phase Ib trial in progressive supranuclear palsy (PSP). AlzProtect is a biotech in Lille, France, fighting neurodegenerative disease. To support the progression of its lead candidate, AZP2006, the company has decided to turn to an unusual source of money that seems to be […] February 15, 2017 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 13 Feb 2017 Biotech from the Bermuda Islands Brings Good News for Dementia Patients Axovant Sciences has announced positive preliminary results from a Phase II trial directed at reducing hallucinations in patients with dementia. Axovant Sciences is a biotech located in Bermuda, a British tropical island in the Atlantic ocean. From there, the company develops drugs against dementia. The company was founded by young biotech entrepreneur Vivek Ramaswamy, which has […] February 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jan 2017 ‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier Ossianix, partnered with Lundbeck, is developing shark antibodies that can help therapeutics cross the blood brain barrier. Ossianix develops shark-inspired antibody fragments, VNARs, with outstanding properties thanks to their small size and high solubility. The company has now received a milestone payment from Danish pharma Lundbeck for the development of the technology as a delivery […] January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2016 Evotec closes the year partnering with Celgene to treat Alzheimer’s Evotec is closing a fantastic financial year with another top-level partnership; Celgene has decided to trust in its iPSC platform to develop drugs for neurodegenerative diseases. Evotec is a successful drug discovery CRO based in Germany that has managed to sign partnerships with some of the biggest names in Biotech. In addition to previous deals with Bayer, Merck, […] December 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2016 Meet the Newest ALS Pioneer Company from Switzerland AL-S Pharma was just born with the only purpose of developing a drug candidate for ALS, a rare condition for which no effective treatments exist. The parents of the newborn company are Neurimmune, a biotech from Zurich that uses high throughput technology to develop treatments for neurodegenerative diseases like Alzheimer’s and Parkinson’s, and TVM Capital Life Science. […] December 8, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2016 CRISPR meets RNAi: a whole new Targeted Therapy Silence Therapeutics just announced preclinical data for a novel CRISPR therapy targeted to the liver using its RNAi delivery expertise. How does it plan to find a space in this challenging and competitive field? Based on the UK’s golden triangle, Silence Therapeutics develops RNAi therapies to treat cancer. Now, it will be applying its targeted RNA delivery […] November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2016 Meet the First Biotech to Jump on Autophagy After This Years’ Nobel Prize Just after the Nobel Prize was awarded to the study of autophagy, PhoreMost announces a collaboration to target the process in neurodegenerative diseases. PhoreMost is a drug discovery company that focuses on finding ‘undruggable’ targets, such as the KRAS cancer gene. Now, the company has announced a collaboration with the University of Cambridge to start working […] October 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2016 World Mental Health Day: How is Biotech Helping the Cause? Biotech is one of the main forces driving the development of effective therapies to treat neurological and mental disorders. For World Mental Health Day yesterday, we want to share with you some of the latest technologies that address these conditions. Yesterday, October 10th, was World Mental Health Day: it is dedicated to raising awareness of neurological and mental disorders […] October 11, 2016 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2016 Another “Almost” against Alzheimers: Lundbeck’s Phase III Flop Alzheimer’s Disease is the most common form of dementia, affecting 15M people across the world. With the most recent failure of idalopirdine, a cure will remain elusive for now. As Derek Lowe observes, “Alzheimers therapies have, for the most part, been a cliff over which people push bales of money.” Unfortunately, the late-stage failure of […] September 27, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2016 UPDATE: AC Immune rakes in €52.5M IPO for assault on Alzheimers It’s not the $700M headlines imply, but AC Immune is winding up to make a splashy IPO of €52.5M to establish itself in the Alzheimer’s Disease space. You might have read about AC Immune‘s ‘$700M IPO’ and thought, “gee, that can’t be right – that sum is roughly half of the total from all European companies […] September 26, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email